Recent Updates
Recently added Catalysts

TV-46000

Phase 3

Schizophrenia | Small molecule | Psychiatry |Teva Pharmaceutical Industries Limited|Last Updated: Mar 10, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials2
Total Enrollment880

FDA Designations

No designations recorded

Clinical trial landscape

TV-46000 · 2 trials · 1 indication

Phase 3 2
NCT03893825A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaSchizophrenia
COMPLETED336 Analytics
NCT03503318Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaSchizophrenia
COMPLETED544 Analytics
PHASE3COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
SchizophreniaUnlock trial analytics
PHASE3COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
SchizophreniaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Adverse Events (AEs)
Baseline up to Week 64

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Number of Participants With SAEs
Baseline up to Week 64

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. The safety analysis set included all participants who received at least 1 dose of TV46000 in TV-46000-CNS-30072 study or in TV46000-CNS-30078 study.

Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set
From randomization up to 108 weeks

Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).

Secondary Endpoints

Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set
From randomization up to 108 weeks
Proportion of Participants With Impending Relapse
Week 24
Number of Participants Who Maintain Stability at the Endpoint
At the endpoint (up to 108 weeks)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TV-46000 q1mEXPERIMENTALParticipants will receive a subcutaneous (SC) injection of TV-46000 at baseline and every 4 weeks (q4w) thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
TV-46000 q2mEXPERIMENTALParticipants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
PlaceboPLACEBO_COMPARATORParticipants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.

Interventions

NameTypeDescription
TV-46000DRUGTV-46000 will be administered per dose and schedule specified in the arm description.
PlaceboDRUGPlacebo matching to TV-46000 will be administered per schedule specified in the arm description.
Unlock Study Design Details

Eligibility Criteria

Age Range13 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites90

Inclusion Criteria: Participants Rolling Over from the Pivotal Efficacy Study TV46000-CNS-30072: * The participant must have participated in the pivotal efficacy study (Study TV46000-CNS-30072) without experiencing relapse events and without important protocol deviations. * If the participant was ...

Countries:United StatesBulgariaCanadaFranceIsrael
Unlock Eligibility Criteria

Frequently asked questions about TV-46000

What is TV-46000 used for in schizophrenia?

TV-46000 is an investigational small molecule being developed as a maintenance treatment for schizophrenia in adult and adolescent participants. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.

Who makes TV-46000?

TV-46000 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker symbol TEVA.

What phase is TV-46000 in?

TV-46000 is in Phase 3 clinical development. Two Phase 3 trials have been completed, both evaluating the drug as a maintenance treatment for schizophrenia. It remains investigational and has not been approved.

What clinical trials is TV-46000 in?

TV-46000 has been studied in two completed Phase 3 trials: NCT03503318, which enrolled 544 participants, and NCT03893825, which enrolled 336 participants. Both trials evaluated the drug as a maintenance treatment for schizophrenia in adults and adolescents.

Is TV-46000 the same as any other drug?

No alternative names for TV-46000 have been reported. It is identified solely by its investigational code name TV-46000 in clinical trial registries.